Skip to Content

Join the 'Fusilev' group to help and get support from people like you.

Fusilev News

FDA Approves Fusilev for Use in Patients with Colorectal Cancer

Posted 2 May 2011 by

IRVINE, Calif.--(BUSINESS WIRE)--Apr 30, 2011 - Spectrum Pharmaceuticals a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, received approval from the U.S. Food and Drug Administration (FDA) on April 29, 2011, for the use of Fusilev (levoleucovorin) in combination with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. This new, expanded indication supplements the original 2008 FDA approval of Fusilev. "We are pleased that the FDA has approved Fusilev for use in colorectal cancer," said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. "Although the NCCN Guidelines in the United States already recommend levoleucovorin in the treatment of colorectal cancer patients, we could not promote Fusilev for this indication ... Read more

Related support groups: Leucovorin, Fusilev

Ask a Question

Further Information

Related Condition Support Groups

Colorectal Cancer, Methotrexate Overdosage, Methotrexate Rescue

Fusilev Patient Information at